ReviewCureus2024
The Pathophysiology and Vascular Complications of Diabetes in Chronic Kidney Disease: A Comprehensive Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Selective glomerular hypofiltration syndrome: a novel renal phenotype associated with cardiovascular disease and adverse outcomes in diabetic kidney disease.BMJ open diabetes research & care · 2026Article
- Can Chronic Pain Accelerate Chronic Kidney Disease? Is Pain a Disease Modifier Rather than a Symptom?Life (Basel, Switzerland) · 2026Article
- [Buffering effect of intensive lipid lowering on mortality risk in type 2 diabetic patients with chronic kidney disease and challenging glycemic management: a cohort study based on dual metabolic trajectories].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Observational
- Blood Flow Restriction Training in Hemodialysis Patients: Clinical Benefits, Challenges, and Future Perspectives.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- Serum Osteoprotegerin Is Associated Independently with Peripheral Arterial Stiffness in Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Article
- From Parallel Programming to Bidirectional Crosstalk: The Brain-Kidney Axis in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Cross-Cultural Adaptation and Validation of the Simplified Diabetes Knowledge Test (Arabic Version) for Insulin-Dependent Diabetic Patients: A Cross-Sectional Study in Iraq.Journal of clinical medicine · 2026Article
- The role of texture analysis of T1 weighted images in diagnosis of chronic kidney disease.Scientific reports · 2026Article
- Stress hyperglycemia ratio (SHR) and triglyceride-glucose index (TYG) associated with renal response to finerenone in diabetic kidney disease: a retrospective cohort study.Frontiers in medicine · 2026Article
- Article
- Web-based Machine Learning Model for Predicting Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Multicenter Study.F1000Research · 2026Article
- Network Analysis of Symptom Clusters and Core Symptoms in Patients with Type 2 Diabetes Mellitus.Patient preference and adherence · 2026Article
- The Triglyceride-Glucose-Chinese Visceral Adiposity Index (TyG-CVAI) outperforms other insulin resistance indices in its association with cardiovascular-kidney-metabolic syndrome severity in type 2 diabetes: a comparative study.Frontiers in nutrition · 2026Article
- A Simplified Machine Learning Model for Predicting Reduced Kidney Function in Thai Patients with Type 2 Diabetes: A Retrospective Study.Journal of clinical medicine · 2025Article
- Texture Analysis of T2-Weighted Images as Reliable Biomarker of Chronic Kidney Disease Microstructural State.Biomedicines · 2025Article
- Benefits of Sodium-Glucose Cotransporter-2 Inhibitors with Renin-Angiotensin System Blockers in Type-2 Diabetes: A Cohort Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis.International journal of molecular sciences · 2025Article
- Recent advances in natural polysaccharides for type 2 diabetes management: sources, structural characteristics, and mechanistic insights.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) represents a significant global health challenge, contributing to substantial morbidity, mortality, and economic burden. T2DM is the leading cause of CKD, and CKD exacerbates diabetes-related complications, creating a bidirectional relationship driven by oxidative stress, inflammation, and endothelial dysfunction. Diabetic kidney disease (DKD), affecting some individuals with T2DM, accelerates progression to end-stage renal disease (ESRD) and increases cardiovascular mortality. Microvascular complications, including nephropathy, retinopathy, and neuropathy, and macrovascular complications, such as coronary artery disease and stroke, are prevalent in this population, further diminishing the quality of life. The pathophysiology underlying these complications is multifaceted. Hyperglycemia-induced oxidative stress and inflammation drive kidney damage and systemic vascular complications, while CKD alters glucose metabolism and antidiabetic drug pharmacokinetics. Endothelial dysfunction exacerbates vascular complications through impaired nitric oxide production and heightened thrombogenicity. Emerging insights into genetic and epigenetic mechanisms, including DNA methylation and mitochondrial dysfunction, have highlighted new therapeutic targets. Management strategies emphasize early screening, glycemic control, and a multidisciplinary approach integrating lifestyle modifications, pharmacotherapy, and patient education. Interventions targeting oxidative stress, inflammation, and endothelial dysfunction have shown promise in mitigating disease progression. Current evidence on the interconnected mechanisms driving DKD and associated vascular complications highlights the critical need for proactive, patient-centered management and further research into innovative diagnostic and therapeutic approaches to address this global health challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.